CEBPA公司
转录因子
髓系白血病
运行x1
医学
癌症研究
白血病
抄写(语言学)
造血
髓样
运行x1t1
基因
发起人
生物信息学
基因表达
生物
遗传学
免疫学
干细胞
哲学
语言学
作者
Susumu Kobayashi,Hisashi Takei
出处
期刊:PubMed
日期:2018-08-07
卷期号:59 (7): 922-931
被引量:1
标识
DOI:10.11406/rinketsu.59.922
摘要
Transcription factors are proteins that bind specific DNA-regulatory sequences and regulate gene transcription. In a hematopoietic system, transcription factors, such as C/EBPα, PU.1, and RUNX1, regulate the expression of essential genes to maintain the homeostasis in the bone marrow. The dysfunction of transcription factors mediated by gene mutations, chromosomal aberration, or aberrant expression can lead to cancer, including acute myeloid leukemia. Previously, transcription factors were not considered as therapeutic targets; however, a better understanding of cancer pathology and mechanisms underlying transcriptional regulation has enabled us to develop therapeutic agents that target transcription factors. C/EBPα is one of the essential transcription factors responsible for granulocytic differentiation and maturation. CEBPA mutation and/or low C/EBPα expression contribute to the pathogenesis of acute myeloid leukemia. Several therapeutic agents have been developed to increase C/EBPα activity, including ICCB280, which is a small molecule we identified by high-throughput screening. We believe that the novel therapeutic approach of targeting transcription factors will benefit patients with acute myeloid leukemia in the near future.
科研通智能强力驱动
Strongly Powered by AbleSci AI